![Atossa Therapeutics Inc](/common/images/company/N_ATOS.png)
Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other brea... Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. Show more
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the...
SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced the appointment of Heather Rees as the Company’s new Chief...
SEATTLE, June 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced protocol changes in the previously initiated study to evaluate...
SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its expected upcoming inclusion in the Russell 3000® Index...
SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor...
SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0505 | 3.88461538462 | 1.3 | 1.43 | 1.272 | 1099775 | 1.38558083 | CS |
4 | 0.2005 | 17.4347826087 | 1.15 | 1.43 | 1.02 | 1099710 | 1.21095829 | CS |
12 | -0.2195 | -13.9808917197 | 1.57 | 1.81 | 1.02 | 1056666 | 1.3754289 | CS |
26 | 0.5164 | 61.9110418415 | 0.8341 | 2.31 | 0.7744 | 1343957 | 1.50315567 | CS |
52 | 0.2205 | 19.5132743363 | 1.13 | 2.31 | 0.62 | 877387 | 1.34591378 | CS |
156 | -2.8495 | -67.8452380952 | 4.2 | 4.57 | 0.5 | 1637176 | 2.13569186 | CS |
260 | -0.6695 | -33.1435643564 | 2.02 | 9.8 | 0.5 | 3508443 | 3.18334773 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.